These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 19561412)

  • 21. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
    Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival.
    Gustafsson Jernberg A; Remberger M; Ringdén O; Winiarski J
    Bone Marrow Transplant; 2003 Feb; 31(3):175-81. PubMed ID: 12621478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic hematopoietic cell transplantation for metastatic breast cancer.
    Ueno NT; Rizzo JD; Demirer T; Cheng YC; Hegenbart U; Zhang MJ; Bregni M; Carella A; Blaise D; Bashey A; Bitran JD; Bolwell BJ; Elfenbein GJ; Fields KK; Freytes CO; Gale RP; Lazarus HM; Champlin RE; Stiff PJ; Niederwieser D
    Bone Marrow Transplant; 2008 Mar; 41(6):537-45. PubMed ID: 18084340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies.
    Sureda A; Schmitz N
    Ann Hematol; 2003 Jan; 82(1):1-13. PubMed ID: 12574957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-cell receptor Vbeta repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
    Hentschke P; Omazic B; Mattsson J; Näsman-Björk I; Lundkvist I; Gigliotti D; Barkholt L; Ringdén O; Remberger M
    Scand J Immunol; 2005 Mar; 61(3):285-94. PubMed ID: 15787747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning.
    Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Jaime-Pérez JC; Treviño-Montemayor OR; Martínez-Cabriales SA; Gómez-Peña A; López-Otero A; Ruiz-Delgado GJ; González-Llano O; Mancías-Guerra MC; Tarín-Arzaga LD; Rodríguez-Romo LN; Ruiz-Argüelles GJ; Gómez-Almaguer D
    Eur J Haematol; 2011 Dec; 87(6):521-30. PubMed ID: 21883482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
    Poiré X; Labopin M; Cornelissen JJ; Volin L; Richard Espiga C; Veelken JH; Milpied N; Cahn JY; Yacoub-Agha I; van Imhoff GW; Michallet M; Michaux L; Nagler A; Mohty M
    Am J Hematol; 2015 Aug; 90(8):719-24. PubMed ID: 26010466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic haematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens.
    Omazic B; Hentschke P; Näsman-Björk I; Mattsson J; Oxelius VA; Ringdén O; Barkholt L; Permert J; Lundkvist I
    Scand J Immunol; 2005 Jan; 61(1):72-81. PubMed ID: 15644125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic haematopoietic stem cell transplantation: current status and future outlook.
    Aschan J
    Br Med Bull; 2006; 77-78():23-36. PubMed ID: 16968691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia.
    Ooi J; Takahashi S; Tomonari A; Tsukada N; Konuma T; Kato S; Kasahara S; Sato A; Monma F; Nagamura F; Iseki T; Tojo A; Asano S
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1341-7. PubMed ID: 19041055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation.
    Graef T; Vaupel M; Fenk R; Ruf L; Zohren F; Germing U; Haas R; Kobbe G
    Hematol Oncol; 2007 Dec; 25(4):170-7. PubMed ID: 17579887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.
    Ringdén O; Labopin M; Ehninger G; Niederwieser D; Olsson R; Basara N; Finke J; Schwerdtfeger R; Eder M; Bunjes D; Gorin NC; Mohty M; Rocha V
    J Clin Oncol; 2009 Sep; 27(27):4570-7. PubMed ID: 19652066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.
    Niederwieser D; Lange T; Cross M; Basara N; Al-Ali H
    Best Pract Res Clin Haematol; 2006; 19(4):825-38. PubMed ID: 16997186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced intensity conditioning allogeneic transplant for advanced chronic lymphocytic leukemia.
    Soligo D; Motta M; Borsotti C; Ibatici A; Cortelezzi A; Lambertenghi Deliliers G
    Haematologica; 2004 Jul; 89(7):885-6. PubMed ID: 15257953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.